Michael Ulz
Stock Analyst at Morgan Stanley
(4.61)
# 210
Out of 5,091 analysts
103
Total ratings
59.68%
Success rate
28.3%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Michael Ulz
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| KYTX Kyverna Therapeutics | Maintains: Overweight | $20 → $25 | $8.27 | +202.30% | 3 | Dec 4, 2025 | |
| ARWR Arrowhead Pharmaceuticals | Maintains: Equal-Weight | $45 → $48 | $68.60 | -30.03% | 6 | Nov 26, 2025 | |
| IONS Ionis Pharmaceuticals | Maintains: Overweight | $90 → $94 | $81.51 | +15.32% | 8 | Oct 30, 2025 | |
| VKTX Viking Therapeutics | Maintains: Overweight | $98 → $102 | $37.98 | +168.56% | 4 | Oct 23, 2025 | |
| MIRM Mirum Pharmaceuticals | Maintains: Overweight | $75 → $81 | $67.90 | +19.29% | 4 | Oct 16, 2025 | |
| KPTI Karyopharm Therapeutics | Maintains: Outperform | $25 → $21 | $5.89 | +256.54% | 8 | Oct 9, 2025 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Equal-Weight | $405 → $475 | $430.02 | +10.46% | 12 | Oct 6, 2025 | |
| SLN Silence Therapeutics | Maintains: Overweight | $45 → $25 | $6.91 | +261.79% | 12 | May 9, 2025 | |
| CABA Cabaletta Bio | Maintains: Overweight | $30 → $22 | $2.48 | +787.10% | 6 | Apr 1, 2025 | |
| AARD Aardvark Therapeutics | Initiates: Overweight | $29 | $13.82 | +109.84% | 1 | Mar 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $24 → $20 | $2.31 | +765.80% | 4 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $18 → $10 | $2.23 | +348.43% | 2 | Feb 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $46 → $96 | $54.65 | +75.66% | 4 | Jan 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $48 → $52 | $22.20 | +134.23% | 2 | Aug 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $3 → $7 | $1.07 | +554.21% | 8 | Feb 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 → $27 | $10.52 | +156.65% | 2 | Aug 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $30 → $20 | $2.39 | +736.82% | 3 | Mar 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $45 | $3.50 | +1,185.71% | 1 | Feb 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $20 → $10 | $0.73 | +1,269.86% | 3 | Jan 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $3 | $5.45 | -44.95% | 1 | Jan 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Equal-Weight | $18 → $30 | $6.58 | +355.93% | 1 | Jan 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $300 → $500 | $27.92 | +1,690.83% | 2 | May 28, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $85 → $80 | $36.45 | +119.48% | 3 | Nov 3, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $12 → $15 | $9.85 | +52.28% | 3 | Jul 12, 2017 |
Kyverna Therapeutics
Dec 4, 2025
Maintains: Overweight
Price Target: $20 → $25
Current: $8.27
Upside: +202.30%
Arrowhead Pharmaceuticals
Nov 26, 2025
Maintains: Equal-Weight
Price Target: $45 → $48
Current: $68.60
Upside: -30.03%
Ionis Pharmaceuticals
Oct 30, 2025
Maintains: Overweight
Price Target: $90 → $94
Current: $81.51
Upside: +15.32%
Viking Therapeutics
Oct 23, 2025
Maintains: Overweight
Price Target: $98 → $102
Current: $37.98
Upside: +168.56%
Mirum Pharmaceuticals
Oct 16, 2025
Maintains: Overweight
Price Target: $75 → $81
Current: $67.90
Upside: +19.29%
Karyopharm Therapeutics
Oct 9, 2025
Maintains: Outperform
Price Target: $25 → $21
Current: $5.89
Upside: +256.54%
Alnylam Pharmaceuticals
Oct 6, 2025
Maintains: Equal-Weight
Price Target: $405 → $475
Current: $430.02
Upside: +10.46%
Silence Therapeutics
May 9, 2025
Maintains: Overweight
Price Target: $45 → $25
Current: $6.91
Upside: +261.79%
Cabaletta Bio
Apr 1, 2025
Maintains: Overweight
Price Target: $30 → $22
Current: $2.48
Upside: +787.10%
Aardvark Therapeutics
Mar 10, 2025
Initiates: Overweight
Price Target: $29
Current: $13.82
Upside: +109.84%
Feb 28, 2025
Maintains: Outperform
Price Target: $24 → $20
Current: $2.31
Upside: +765.80%
Feb 3, 2025
Maintains: Overweight
Price Target: $18 → $10
Current: $2.23
Upside: +348.43%
Jan 28, 2025
Maintains: Overweight
Price Target: $46 → $96
Current: $54.65
Upside: +75.66%
Aug 14, 2024
Maintains: Overweight
Price Target: $48 → $52
Current: $22.20
Upside: +134.23%
Feb 27, 2024
Maintains: Equal-Weight
Price Target: $3 → $7
Current: $1.07
Upside: +554.21%
Aug 16, 2023
Maintains: Outperform
Price Target: $15 → $27
Current: $10.52
Upside: +156.65%
Mar 24, 2023
Maintains: Equal-Weight
Price Target: $30 → $20
Current: $2.39
Upside: +736.82%
Feb 1, 2023
Initiates: Overweight
Price Target: $45
Current: $3.50
Upside: +1,185.71%
Jan 27, 2023
Maintains: Overweight
Price Target: $20 → $10
Current: $0.73
Upside: +1,269.86%
Jan 27, 2023
Downgrades: Equal-Weight
Price Target: $3
Current: $5.45
Upside: -44.95%
Jan 27, 2023
Upgrades: Equal-Weight
Price Target: $18 → $30
Current: $6.58
Upside: +355.93%
May 28, 2020
Maintains: Outperform
Price Target: $300 → $500
Current: $27.92
Upside: +1,690.83%
Nov 3, 2017
Maintains: Outperform
Price Target: $85 → $80
Current: $36.45
Upside: +119.48%
Jul 12, 2017
Maintains: Outperform
Price Target: $12 → $15
Current: $9.85
Upside: +52.28%